FDA
-
-
-
-
-
-
-
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
-
-
-
-
-
-
-
Atea Pharmaceuticals (AVIR) Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway
-
-
-
-
-
-
-
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Atea Pharmaceuticals (AVIR) Granted FDA Fast Track Designation Granted for AT-752
-
-
-
-
-
-
-
After-Hours Stock Movers 11/16: (CEMI) (LZB) (VREX) Higher; (AVIR) (STNE) (DLB) Lower (more...)
-
-
-
-
-
-
-
Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update
-
-
-
-
-
-
322,199 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

